{"schema_version":"1","generated_at":"2026-10-28T13:25:30.298Z","data_as_of":null,"url":"https://www.findmykol.com/kol/otto-metzger","json_url":"https://www.findmykol.com/kol/otto-metzger/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"otto-metzger","name":"Otto Metzger","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Dana-Farber Cancer Institute","institution_url":"https://www.findmykol.com/institution/dana-farber-cancer-institute","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1275875155","orcid":"0000-0003-0792-0320","openalex":"A5026132340"},"summary":"Otto Metzger is an Oncology physician affiliated with Dana-Farber Cancer Institute. OpenAlex indexes 320 publications with 8,794 citations (h-index 39); ClinicalTrials.gov lists 5 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":320,"cited_by_count":8794,"h_index":39,"latest_activity_year":2025,"source":"works"},"trials":{"count":5,"shown":3,"withheld":2,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05128773","title":"Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity","phase":"PHASE3","status":"TERMINATED","role":"Overall official","sponsor":"Sanofi","source_url":"https://clinicaltrials.gov/study/NCT05128773","trial_url":"https://www.findmykol.com/trial/NCT05128773"},{"nct":"NCT03304756","title":"Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"Instituto Nacional de Cancer, Brazil","source_url":"https://clinicaltrials.gov/study/NCT03304756","trial_url":"https://www.findmykol.com/trial/NCT03304756"},{"nct":"NCT02764541","title":"Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"Dana-Farber Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT02764541","trial_url":"https://www.findmykol.com/trial/NCT02764541"}],"source":"trials"},"payments":{"company_count":8,"program_years":{"first":2021,"last":null},"rows_total":12,"shown":3,"withheld":9,"rows":[{"payer":"PFIZER INC.","program_year":2025,"amount_usd":20455.39,"payment_count":9,"source_url":"https://openpaymentsdata.cms.gov/search?query=1275875155"},{"payer":"AstraZeneca UK Limited","program_year":2025,"amount_usd":2050,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1275875155"},{"payer":"JAZZ PHARMACEUTICALS INC.","program_year":2025,"amount_usd":1648,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1275875155"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1275875155","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer","year":2025,"journal":"JAMA","source_url":"https://doi.org/10.1001/jama.2024.26886","status":"verified"},{"title":"Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium","year":2024,"journal":"The Lancet Regional Health - Europe","source_url":"https://doi.org/10.1016/j.lanepe.2024.101005","status":"verified"},{"title":"HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial","year":2024,"journal":"Journal of Clinical Investigation","source_url":"https://doi.org/10.1172/jci176454","status":"verified"},{"title":"Assessment of the HER2DX Assay in Patients With <i>ERBB2</i>-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab","year":2023,"journal":"JAMA Oncology","source_url":"https://doi.org/10.1001/jamaoncol.2023.0181","status":"verified"},{"title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","year":2022,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2022.01.009","status":"verified"}],"source":"works"},"contact":{"address_1":"450 BROOKLINE AVE","city":"Boston","state":"MA","zip":"022155418","phone":"617-763-3110","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1275875155","source":"identity"},"similar":[{"name":"Kenneth Anderson","slug":"kenneth-anderson","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/kenneth-anderson","json_url":"https://www.findmykol.com/kol/kenneth-anderson/profile.json"},{"name":"Frank Hodi","slug":"frank-hodi","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/frank-hodi","json_url":"https://www.findmykol.com/kol/frank-hodi/profile.json"},{"name":"Paul Richardson","slug":"paul-richardson","institution":"Dana-Farber Cancer Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/paul-richardson","json_url":"https://www.findmykol.com/kol/paul-richardson/profile.json"},{"name":"Toni Choueiri","slug":"toni-choueiri","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/toni-choueiri","json_url":"https://www.findmykol.com/kol/toni-choueiri/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":2,"payments":9,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2013-03-19","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}